Core Viewpoint - cbdMD, Inc. has successfully satisfied its Senior Secured Convertible Notes, enhancing its financial position and becoming debt-free, excluding normal operational accounts payable [1][2]. Company Overview - cbdMD, Inc. is a leading and trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs [1][3]. - The company offers a comprehensive line of U.S. produced, THC-free CBD products, including tinctures, gummies, topicals, capsules, sleep aids, and drink products [3]. Financial Position - The full conversion of the Notes into common stock has strengthened the company's financial position, increased cash reserves, and provided greater flexibility for capital allocation [2]. - As of January 14, 2025, there are 6,262,833 shares of the company's common stock issued and outstanding [1].

Core Viewpoint - cbdMD, Inc. has successfully reduced the principal amount of its Senior Secured Convertible Notes to approximately $56,000 as of January 8, 2025, following conversions by certain note holders [1][2]. Group 1: Financial Performance - The company has issued a total of 609,717 shares of common stock due to conversion requests, resulting in a reduction of approximately $309,000 in principal, in addition to accrued interest [2]. - As of January 8, 2024, cbdMD has 6,152,841 shares of common stock issued and outstanding [2]. - At the end of the first fiscal quarter, the company reported cash and cash equivalents of approximately $2.1 million, indicating a strong liquidity position to start calendar 2025 [3]. Group 2: Company Overview - cbdMD is recognized as a leading and trusted cannabidiol (CBD) brand, offering a comprehensive line of U.S. produced, THC-free CBD products, including NSF Certified for Sport® products and Full Spectrum products [4]. - The company's product range includes CBD tinctures, gummies, topicals, capsules, sleep aids, and drink products, as well as veterinarian-formulated pet products under the Paw CBD brand [4].

Company Compliance Issues - cbdMD received a notice from NYSE American on December 31, 2024, stating noncompliance with Section 1003(a)(i) of the NYSE American Company Guide due to stockholders' equity of $1,963,417 as of September 30, 2024, which is below the required $2 million [1] - The company reported losses from continuing operations and/or net losses in four of its five most recent fiscal years [1] - cbdMD remains subject to a compliance plan accepted by NYSE American on August 20, 2024, to address noncompliance under Section 1003(a)(ii) due to stockholders' equity under $4 million [2] - The company must regain compliance by December 5, 2025, or face delisting procedures [2] Stock Listing and Trading - The notice has no immediate impact on the listing of cbdMD's common stock (YCBD) or Series A Preferred Stock (YCBD-PA), which will continue to trade on NYSE American during the compliance plan period [3] - Both stocks will trade with the designation "BC" to indicate "below compliance" status [3] Financial Performance and Strategy - cbdMD reduced cash consumption from $4.9 million in fiscal 2023 to approximately $0.7 million in fiscal 2024, with a significant reduction in the second half of fiscal 2024 [4] - The company is considering transactions, including converting Preferred Stock and its accrued dividend ($4.67 million as of September 30, 2024) into Common Stock, to increase stockholders' equity [4] Company Overview - cbdMD is a leading CBD company with brands including cbdMD, Paw CBD, and ATRx Labs, offering a comprehensive line of THC-free CBD products and Full Spectrum products [5][6] - The company's products include CBD tinctures, gummies, topicals, capsules, sleep aids, and Farm Act compliant Delta 9 products, as well as pet products and functional mushroom support [6]

Company Overview - cbdMD, Inc. is a leading and highly trusted cannabidiol (CBD) brand, offering a comprehensive line of U.S. produced, THC-free CBD products, including NSF Certified for Sport® products and new Full Spectrum products [2] - The product range includes CBD tinctures, gummies, topicals, capsules, bath bombs, sleep aids, drink mixes, and pet products under the Paw CBD brand, as well as natural functional mushroom products under the ATRx brand [2] Leadership and Strategic Developments - T. Ronan Kennedy, the CEO and CFO of cbdMD, has been appointed to the Board of Directors, effective December 18, 2024, expanding the board to five members [7] - Under Kennedy's leadership, cbdMD has implemented a turnaround strategy that has resulted in substantial cost savings, improved profitability metrics, and established a foundation for future growth [1][8] - The company has made significant progress in optimizing its cost structure and enhancing operational fundamentals, positioning itself for long-term success as it enters 2025 with a stronger cash position and growth opportunities [8]

cbdMD Generates $19.1 Million in Year Over Year Reduction in Net Loss ImprovementFinishes the year with a stronger cash position.December 18, 2024 4:08 PM EST | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - December 18, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs toda ...

cbdMD, Inc. to Host Conference Call to Discuss September 30, 2024 Fourth Quarter and Fiscal Year 2024 ResultsDecember 18, 2024 11:04 AM EST | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - December 18, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, December 18, 2024, to discuss the company's ...

Company Announcement - cbdMD, Inc. has postponed the release of its financial results and conference call for the fourth quarter and fiscal year ended September 30, 2024, which was originally scheduled for December 17, 2024 [2] - The new expected date for the financial results release is after market close on December 18, 2024, with the conference call scheduled for the same day at 4:20 PM EST [2] Company Overview - cbdMD, Inc. is a leading and trusted cannabidiol (CBD) brand, offering a comprehensive line of U.S. produced, THC-free CBD products, including NSF Certified for Sport® products and new Full Spectrum products [3] - The product range includes CBD tinctures, gummies, topicals, capsules, bath bombs, sleep aids, and Delta 9 products, as well as veterinarian-formulated pet products under the Paw CBD brand [3]

Group 1 - cbdMD, Inc. will host a conference call on December 17, 2024, at 4:20 p.m. Eastern Time to discuss its financial results for the fourth quarter and fiscal year 2024 [2][3] - The conference call will provide insights into the company's business progress and financial performance as of September 30, 2024 [2] - The call can be accessed via specific dial-in numbers for USA/Canada and international participants, with a replay option available [3] Group 2 - cbdMD, Inc. is recognized as a leading brand in the hemp-derived cannabidiol (CBD) market, offering a wide range of THC-free and Full Spectrum products [4] - The company's product line includes tinctures, gummies, topicals, capsules, and pet products under the Paw CBD brand, as well as functional mushroom supplements through ATRx Labs [4] - cbdMD emphasizes its commitment to quality and trust, with products produced in the U.S. and a focus on consumer accessibility through various retail outlets [4]

. ● . cbdMD, Inc. Announces Acceptance of Compliance Plan by NYSE American August 26, 2024 4:25 PM EDT | Source: cbdMD Charlotte, North Carolina--(Newsfile Corp. - August 26, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs, today announced that it received notice from the NYSE American LLC that it ha ...

Core Insights - cbdMD reported sequential revenue growth and positive net income for Q3 2024, achieving significant operational improvements and a reduction in operating losses [2][3][4]. Financial Performance - Net sales for Q3 2024 totaled $5.1 million, a decrease of 15% year-over-year from $6.1 million, but an increase of 18% sequentially [5]. - Direct to consumer (DTC) net sales were $3.9 million, accounting for 76% of total net sales, down from $4.9 million year-over-year but up 9% sequentially [6]. - Wholesale net sales increased to $1.2 million, a 10% increase from the previous year [6]. - Gross profit margin improved to 65% in Q3 2024 compared to 63% in Q2 2023 [7]. - The company reported a net income of approximately $0.46 million for Q3 2024, compared to a net loss of approximately $1.7 million in Q3 2023 [9]. Operational Efficiency - The operational loss decreased significantly from $1.8 million in Q3 2023 to $0.38 million in Q3 2024 [3][7]. - Non-GAAP adjusted loss from operations was approximately $0.08 million, down from $0.60 million in the same quarter last year, marking the lowest non-GAAP adjusted EBITDA loss since going public [8]. - The company achieved over $200,000 in monthly operating cost savings as of August 2024 [15]. Compliance and Business Updates - cbdMD received a notification from NYSE American regarding non-compliance with continued listing standards and submitted a compliance plan [12]. - The company terminated its former executive office lease effective August 1, 2024, which will eliminate future lease liabilities [14]. - During the quarter, 714,229 common shares were issued due to the conversion of convertible promissory notes [13]. Cash and Working Capital - As of June 30, 2024, the company had negative working capital of approximately $567,000, reduced by $3.7 million in accrued dividend payments [11]. - Cash on hand increased to approximately $2.3 million from $1.8 million at the end of September 2023 [11].